InvestorsObserver is giving SAB Biotherapeutics Inc (SABS) an Analyst Rating Rank of 74, meaning SABS is ranked higher by analysts than 74% of stocks. The average price target for SABS is $19.375 and analyst’s rate the stock as a Strong Buy.
Wall Street analysts are rating SABS a Strong Buy today. Find out what this means to you and get the rest of the rankings on SABS!
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With SAB Biotherapeutics Inc Stock Today?
SAB Biotherapeutics Inc (SABS) stock is trading at $8.77 as of 10:21 AM on Monday, Dec 20, a decline of -$0.01, or -0.09% from the previous closing price of $8.78. The stock has traded between $8.66 and $9.09 so far today. Volume today is less active than usual. So far 18,229 shares have traded compared to average volume of 435,463 shares.
Click Here to get the full Stock Report for SAB Biotherapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
